// App-Quantinova.ai

TPS5096 : Randomised phase III trial of enzalutamide in androgen deprivation therapy (ADT) with radiation therapy for clinically localised, high risk, or node-positive prostate cancer: ENZARAD (ANZUP 1303).

Researchers

Presenter

  • Scott Williams

Principal Investigators

  • Ian D. Davis

  • Christopher Sweeney

  • Martin R. Stockler

  • Andrew James Martin

  • Wendy Hague

  • Xanthi Coskinas

  • Sonia Yip

  • Emily Tu

  • Nicola Jane Lawrence

  • Ray McDermott

  • Paul J. Kelly

  • Olwyn Deignan

  • Simon Hughes

  • Valerie Fonteyne

  • Bertrand F. Tombal

  • Paul L. Nguyen

Medical Centers

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • Monash University and Eastern Health, Victoria, Australia

  • Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA

  • NHMRC Clinical Trials Centre, The University of Sydney, Sydney, Australia

  • Sydney Catalyst Translational Cancer Research Centre, Sydney, Australia

  • ICORG, Dublin, Ireland

  • Cork University Hospital, Cork, Ireland

  • Cancer Trials Ireland, Dublin, Ireland

  • Guy's And St Thomas NHS Foundation Trust, London, United Kingdom

  • Ghent University Hospital, Ghent, Belgium

  • Cliniques Universitaires Saint-Luc, UCL, Brussels, MN, Belgium

  • Department of Radiation Oncology and Radiology, Dana-Farber Cancer Institute, Brigham and Womens Hospital, Harvard Medical School, Boston, MA

Locations

  • Ireland

  • United Kingdom

  • Australia

  • United States

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • Prostate specific antigen

Drug/Treatment

  • Enzalutamide

  • Androgen Tear

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

Phase

  • III

Study Id's

  • NCT02446444

  • ACTRN12614000126617

  • ANZCTR

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved